Back to search
FDAFDA · Food and drugs·Recall number D-0856-2017

DORAMA-NEO (naphazoline hydrochloride) Eye wash, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-020-01

Published May 31, 2017 · Recall initiated: February 16, 2017

Summary

FDA records drug Class II recall D-0856-2017, published May 31, 2017 and initiated February 16, 2017. Recalling firm: Sato Pharmaceutical Inc.; Status: Terminated; Reported quantity: 14,325 bottles; Lot: Lot #: WXTZ, Exp. Sep 2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sato Pharmaceutical Inc.
Distributor
US: Hawaii, Guam, Saipan, SPI
Lot
Lot #: WXTZ, Exp. Sep 2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was DORAMA-NEO (naphazoline hydrochloride) Eye wash, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-020-01 recalled?

Yes. FDA published recall D-0856-2017 on May 31, 2017. Reported hazard: Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

What should I do if I have this product?

Voluntary: Firm initiated · Letter